Promoted Content
Promoted Content

Find Approved Drugs for Cardiology/Vascular Diseases in Clinical Development in UNITED KINGDOM

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Rosuvastatin

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Crestor

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Grunenthal

            Deal Size: $350.0 million Upfront Cash: Undisclosed

            Deal Type: Agreement February 10, 2021

            Details:

            Under the terms of this agreement, Grünenthal has acquired the exclusive rights to market CRESTOR™ and its second brands in more than 30 European markets.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Dapagliflozin

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Forxiga

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 04, 2021

            Details:

            Forxiga is the first SGLT2 inhibitor approved in China for heart failure with reduced ejection fraction in adult patients with and without type-2 diabetes. Approval was based on positive results from the landmark DAPA-HF Phase III trial.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Candesartan Cilexetil

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Atacand

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Cheplapharm Arzneimittel Gmbh

            Deal Size: $400.0 million Upfront Cash: Undisclosed

            Deal Type: Divestment January 04, 2021

            Details:

            AstraZeneca has completed the divestment of commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in over 70 countries to Cheplapharm Arzneimittel GmbH (Cheplapharm).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Rosuvastatin

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Crestor

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Grunenthal

            Deal Size: $350.0 million Upfront Cash: $320.0 million

            Deal Type: Divestment December 01, 2020

            Details:

            Crestor is a statin approved for the treatment of dyslipidaemia and hypercholesterolaemia. The deal will give Gruenenthal rights to sell Crestor and associated medicines in more than 30 countries in Europe, except the UK and Spain.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Dexrazoxane

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Totect

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 10, 2020

            Details:

            Totect® now can be used for reducing the incidence and severity of cardiomyopathy associated with doxorubicin in women with breast cancer who have received a cumulative doxorubicin dose of 300 mg/m² and who will continue to receive doxorubicin therapy.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ticagrelor,Acetylsalicylic Acid

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Brilinta

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 06, 2020

            Details:

            The approval by the US FDA was based on positive results from the THALES Phase III trial that showed aspirin plus Brilinta 90mg significantly reduced the rate of the composite of stroke and death compared to aspirin alone in patients with acute ischaemic stroke or TIA.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Dapagliflozin

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Forxiga

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 05, 2020

            Details:

            Forxiga is the first SGLT2 inhibitor approved in the EU for heart failure with reduced ejection fraction in adult patients with and without type-2 diabetes.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Candesartan Cilexetil

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Atacand

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Cheplapharm Arzneimittel Gmbh

            Deal Size: $400.0 million Upfront Cash: Undisclosed

            Deal Type: Divestment October 30, 2020

            Details:

            AstraZeneca would sell rights for its heart failure and blood pressure medicines Atacand and Atacand Plus to Germany’s Cheplapharm Arzneimittel GmbH. Agreement supports strategy of focusing on newer medicines in main therapy areas.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Dapagliflozin

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Farxiga

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 28, 2020

            Details:

            China’s NMPA has updated the label for AstraZeneca’s Forxiga to include data from the DECLARE-TIMI 58 Phase III trial. This trial demonstrated that Forxiga reduced the risk of composite of hospitalisation for heart failure or cardiovascular death in type-2 diabetes.